MetaVia Inc. (MTVA)

Market Cap	8.06M -32.5%
Revenue (ttm)	n/a
Net Income	-12.97M
EPS	-7.35
Shares Out	5.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,416
Open	1.550
Previous Close	1.520
Day's Range	1.509 - 1.620
52-Week Range	1.170 - 19.029
Beta	0.34
Analysts	Strong Buy
Price Target	26.50 (+1,598.72%)
Earnings Date	May 13, 2026

About MTVA

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: MTVA
• Website: https://www.metaviatx.com

Analyst Summary

According to 2 analysts, the average rating for MTVA stock is "Strong Buy." The 12-month stock price target is $26.5, which is an increase of 1,598.72% from the latest price.

Price Target

$26.5

(1,598.72% upside)

Analyst Consensus: Strong Buy